Hematology

ORR of 80% at recommended dose of talquetamab, teclistamab but with high rates of grade 3/4 AEs

Study suggests that driver mutation monitoring could become standard practice, researcher says

Treatment tied to higher recovery odds and faster time to kidney recovery

FDA boxed warning led to multiple studies on the issue in 2024

News, features, and commentary about cancer-related issues

Studies show promising EFS, PFS, and OS at 3 to 8 years

3-year disease-free survival rate was 96% with blinatumomab versus 87.9% with chemo alone

Experts weigh the role of MRD in personalizing treatment but caution against premature changes

News, features, and commentary about cancer-related issues

"I thought he was helping me"

Reduced toxicity and improved convenience position new treatments for broader use

Rapid evaluation and novel therapies may improve outcomes for these patients

Ponatinib-blinatumomab led to durable remissions without transplant in most, but 13% relapsed

News, features, and commentary about cancer-related issues